research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
Search
for
Sort by
Research
210-240 / 423 results research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Etiopathogenesis of Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Advances in the Treatment of Autosomal Recessive Congenital Ichthyosis: A Look Towards the Repositioning of Drugs
Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
research Type 2 Innate Immunity Regulates Hair Follicle Homeostasis to Control Demodex Pathosymbionts
A specific immune response helps control mite populations on the skin, maintaining healthy hair follicles.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research British Society for Dermatopathology 2011 Findings
Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
research Predictive Modeling of Patient Response to JAK/STAT Inhibitors and Dynamic Patient-Matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Alopecia Areata: Treatment Options and Efficacy
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
Restoring hair bulb immune privilege is crucial for managing alopecia areata.
research Treatment of Alopecia Areata: An Australian Expert Consensus Statement
Alopecia areata treatment varies, with no optimal method established yet.
research Choreographing Immunity in the Skin Epithelial Barrier
The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.
research Role of Bulge Epidermal Stem Cells and TSLP Signaling in Psoriasis
Blocking TSLP reduces skin inflammation and cell overgrowth in psoriasis.
research Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.
research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
research Oxidative Stress and Alopecia Areata
Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.
research Perifolliculitis Capitis Abscedens Et Suffodiens Treatment With Tumor Necrosis Factor Inhibitors and Baricitinib: A Case Report and Literature Review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
research Review of the 2024 American Academy of Dermatology Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
research The Pattern and Clinical Profile of Alopecia Areata: Panoramic Review, Update, and Advances on Etiopathogenesis, Associated Factors, Diagnosis, Complications, Management, and Prognosis in Treatment 2023
Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.
research Ruxolitinib Protects Skin Stem Cells And Maintains Skin Homeostasis In Murine Graft-Versus-Host Disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Dupilumab Therapy for Alopecia Areata in a 4-Year-Old Patient Resistant to Baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Interleukin-15 Is a Hair Follicle Immune Privilege Guardian
Interleukin-15 can help hair growth and protect hair follicles.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research Alopecia Areata in Latin America: Where Are We and Where Are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.